[Use of demeclotetracycline in the treatment of hyponatremia in cirrhotic ascitis].
The activity of demeclotetracyclin, and ADH antagonist, is studied in 11 ethylic patients with cirrhosis of the liver, under a large hydric diet (1500 cm3). The prescription of the cyclin (600 mg daily) is always determined by a fall of the urinary osmolarity (-36%) and by a dramatic improvement of the free water clearance (+ 60%); consecutively, we observe an increase of natremia in 8 out of 9 cases. Associated with Spironolactone (200 mg daily) the anti-ADH activity persists (the free water clearance becomes positive in 5 out of 10 patients), in spite of the natriuretic activity of anti-aldosterone ; a minimal fall of the natremia is observed in only 2 cases. The indication of Demeclotetracyclin in the curative or preventive treatment of the hyponatremia of the liver cirrhosis is discussed.
D000328:Adult; D000368:Aged; D001201:Ascites / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003707:Demeclocycline / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004487:Edema / Q000188:drug therapy; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy*; D008103:Liver Cirrhosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D013148:Spironolactone / Q000627:therapeutic use; D014667:Vasopressins / Q000037:antagonists & inhibitors
D014667:Vasopressins; D013148:Spironolactone; D003707:Demeclocycline
Utilisation de la déméclotétracycline pour le traitement de l'hyponatrémie des ascites cirrhotiques